ALB and hepatocellular carcinoma: Another study conducted by Tada et al. [100] revealed that a high pre-treatment serum modified ALB–BIL grade was a factor that was independently correlated with worse OS in HCC patients receiving molecular targeted therapy with lenvatinib.